A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes

A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes

The current study aimed to evaluate the efficacy of sitagliptin vs. placebo in treating non-alcoholic fatty liver disease (NAFLD). In a triple-blind randomized clinical trial, we assigned 120 eligible subjects with NAFLD to receive daily dosing of 50 mg sitagliptin (n = 60) or the placebo (n = 60) f...

全面介紹

書目詳細資料
Main Authors: Azam Doustmohammadian, Ahmad Nezhadisalami, Fahimeh Safarnezhad Tameshke, Nima Motamed, Mansooreh Maadi, Mohammad Farahmand, Masoudreza Sohrabi, Cain C. T. Clark, Hossein Ajdarkosh, Amir Hossein Faraji, Mehdi Nikkhah, Elham Sobhrakhshankhah, Ramin Ebrahimi, Farhad Zamani
格式: Article
語言:English
出版: Frontiers Media S.A. 2022-07-01
叢編:Frontiers in Medicine
主題:
sitagliptin
NAFLD
clinical trial design
fibrosis scores
liver enzymes
在線閱讀:https://www.frontiersin.org/articles/10.3389/fmed.2022.937554/full

因特網

https://www.frontiersin.org/articles/10.3389/fmed.2022.937554/full

相似書籍